Evidence map›Paper›PMID 28386017›Full record

ArticleCancer research2017

Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma.

Valentina Di Gialleonardo, Hannah N Aldeborgh, Vesselin Miloushev, Kelly M Folkers, Kristin Granlund, William D Tap, Jason S Lewis, Wolfgang A Weber, Kayvan R Keshari

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Hyperpolarized [1-Molecular imaging and biology · 2022
    Article
  4. On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping.International journal of molecular sciences · 2022
    Review
  5. Article
  6. Review
  7. Dynamic volumetric hyperpolarizedMagnetic resonance in medicine · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Targeting tumor-associated acidity in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2018
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Valentina Di GialleonardoRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Hannah N AldeborghRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Vesselin MiloushevRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Kelly M FolkersRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Kristin GranlundRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
William D TapMedicine Memorial Sloan Kettering Cancer Center, New York, New York.
Jason S LewisRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Wolfgang A WeberRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Kayvan R KeshariRadiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. rahimikk@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Human Tissue Culture Bioreactor and Hyperpolarized MR for Biomarker DiscoveryR00EB014328 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI KESHARI, KAYVAN R · 2013 to 2015
$735k
NCI NIH HHS P30 CA008748NIBIB NIH HHS R00 EB014328
6 · The paper itself

Abstract

Biomarkers predicting rapalog responses in sarcomas where PI3K and mTOR are often hyperactivated could improve the suitable recruitment of responsive patients to clinical trials. PI3K/mTOR pathway activation drives energy production by regulating anaerobic glycolysis in cancer cells, suggesting a route toward a monitoring strategy. In this study, we took a multimodality approach to evaluate the phenotypic effects and metabolic changes that occur with inhibition of the PI3K/mTOR pathway. Its central role in regulating glycolysis in human sarcomas was evaluated by short- and long-term rapamycin treatment in sarcoma cell lines. We observed an overall decrease in lactate production

Indexed as

AnimalsCell Line, TumorCell ProliferationHumansMagnetic Resonance ImagingMiceNuclear Magnetic Resonance, BiomolecularSarcomaSignal TransductionXenograft Model Antitumor Assays

Identifiers

PMID28386017
PMCPMC5457322
OpenAlexW2604770294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.